NEFL and amyotrophic lateral sclerosis: A recent genetic trial involving the antisense oligonucleotide tofersen in SOD1-related ALS further confirms the role of NfL as a prognostic biomarker since early reductions of NfL were able to predict the subsequent slowing of ALSFRS-R decline after Tofersen treatment [288].